NASDAQ:SPRO

Spero Therapeutics Stock Earnings Reports

etoro logo Buy SPRO
*Your capital is at risk
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026

Spero Therapeutics Earnings Calls

Mar 31, 2026
-$0.130 (27.78%)
Release date May 13, 2026
EPS estimate -$0.180
EPS actual -$0.130
EPS Surprise 27.78%
Revenue estimate 258K
Revenue actual 258K
Dec 31, 2025
$0.530 (365.00%)
Release date Mar 26, 2026
EPS estimate -$0.200
EPS actual $0.530
EPS Surprise 365.00%
Revenue estimate 26M
Revenue actual 41.297M
Revenue Surprise 58.83%
Sep 30, 2025
-$0.130 (48.00%)
Release date Nov 13, 2025
EPS estimate -$0.250
EPS actual -$0.130
EPS Surprise 48.00%
Revenue estimate 12M
Revenue actual 3.048M
Revenue Surprise -74.60%
Jun 30, 2025
-$0.0300 (92.11%)
Release date Aug 12, 2025
EPS estimate -$0.380
EPS actual -$0.0300
EPS Surprise 92.11%
Revenue estimate 11M
Revenue actual 11.802M
Revenue Surprise 7.29%

Last 4 Quarters for Spero Therapeutics

Below you can see how SPRO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Jun 30, 2025 Beat
Release date Aug 12, 2025
Price on release $2.36
EPS estimate -$0.380
EPS actual -$0.0300
EPS surprise 92.11%
Date Price
Aug 06, 2025 $2.26
Aug 07, 2025 $2.17
Aug 08, 2025 $2.19
Aug 11, 2025 $2.20
Aug 12, 2025 $2.36
Aug 13, 2025 $1.94
Aug 14, 2025 $1.98
Aug 15, 2025 $1.91
Aug 18, 2025 $1.91
4 days before 4.42%
4 days after -19.07%
On release day -17.80%
Change in period -15.49%
Sep 30, 2025 Beat
Release date Nov 13, 2025
Price on release $2.44
EPS estimate -$0.250
EPS actual -$0.130
EPS surprise 48.00%
Date Price
Nov 07, 2025 $2.46
Nov 10, 2025 $2.50
Nov 11, 2025 $2.62
Nov 12, 2025 $2.66
Nov 13, 2025 $2.44
Nov 14, 2025 $2.41
Nov 17, 2025 $2.43
Nov 18, 2025 $2.47
Nov 19, 2025 $2.38
4 days before -0.81%
4 days after -2.46%
On release day -1.23%
Change in period -3.25%
Dec 31, 2025 Beat
Release date Mar 26, 2026
Price on release $2.37
EPS estimate -$0.200
EPS actual $0.530
EPS surprise 365.00%
Date Price
Mar 20, 2026 $2.37
Mar 23, 2026 $2.35
Mar 24, 2026 $2.37
Mar 25, 2026 $2.41
Mar 26, 2026 $2.37
Mar 27, 2026 $2.33
Mar 30, 2026 $2.24
Mar 31, 2026 $2.34
Apr 01, 2026 $2.45
4 days before 0%
4 days after 3.38%
On release day -1.69%
Change in period 3.38%
Mar 31, 2026 Beat
Release date May 13, 2026
Price on release $2.44
EPS estimate -$0.180
EPS actual -$0.130
EPS surprise 27.78%
Date Price
May 07, 2026 $2.51
May 08, 2026 $2.56
May 11, 2026 $2.55
May 12, 2026 $2.54
May 13, 2026 $2.44
May 14, 2026 $2.76
May 15, 2026 $2.79
May 18, 2026 $2.58
May 19, 2026 $2.59
4 days before -2.79%
4 days after 6.15%
On release day 13.11%
Change in period 3.19%

Spero Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for SPRO?
Spero Therapeutics Inc. (SPRO) has scheduled its earnings report for Aug 11, 2026 after the markets close.

What is the SPRO price-to-earnings (P/E) ratio?
SPRO P/E ratio as of Jun 03, 2026 (TTM) is 10.64.

What is the SPRO EPS forecast?
The forecasted EPS (Earnings Per Share) for Spero Therapeutics Inc. (SPRO) for the first fiscal quarter 2026 is -$0.170.

What are Spero Therapeutics Inc.'s retained earnings?
On its balance sheet, Spero Therapeutics Inc. reported retained earnings of $258.00 thousand for the latest quarter ending Mar 31, 2026.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT SPERO THERAPEUTICS INC.
Spero Therapeutics
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct actin...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE